Combination of | |
---|---|
Alendronic acid | Bisphosphonate |
Colecalciferol | Vitamin |
Clinical data | |
Trade names | Fosamax Plus D, Fosavance, Adrovance, others |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Alendronic acid/colecalciferol, sold under the brand name Fosamax Plus D among others, is a medication for the treatment of osteoporosis in men or in postmenopausal women.[2][1][3][5]
Alendronic acid/colecalciferol was approved for use in the United States and in the European Union in 2005.[6][4]
References
- 1 2 "Fosavance Tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 1 March 2020.
- 1 2 "Fosamax Plus D- alendronate sodium and cholecalciferol tablet". DailyMed. 16 August 2019. Retrieved 1 March 2020.
- 1 2 "Adrovance EPAR". European Medicines Agency (EMA). 26 February 2020. Retrieved 1 March 2020.
- 1 2 "Fosavance EPAR". European Medicines Agency (EMA). 9 October 2019. Retrieved 1 March 2020.
- ↑ Von Schacht E, Dambacher MA, Ringe JD, Dukas L (April 2012). "[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence]". MMW Fortschritte der Medizin (in German). 154 (Suppl 1): 10–21. PMID 23427364.
- ↑ "Drug Approval Package: Fosamax Plus D (Alendronate Sodium) NDA #021762". U.S. Food and Drug Administration (FDA). 8 June 2006. Retrieved 1 March 2020.
External links
- "Alendronate sodium mixture with cholecalciferol". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.